Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7053 · 1 trial · 1 indication
The safety and tolerability after multiple doses of AZD7503 in healthy Japanese participants will be evaluated.
| Arm | Type | Description |
|---|---|---|
| AZD7503 | EXPERIMENTAL | Participants will subcutaneously receive AZD7503. |
| Placebo | PLACEBO_COMPARATOR | Participants will subcutaneously receive placebo. |
| Name | Type | Description |
|---|---|---|
| AZD7053 | DRUG | Randomised participants will receive AZD7503 subcutaneously. |
| Placebo | DRUG | Randomised participants will receive placebo subcutaneously. |
Inclusion Criteria: * For Japanese participants: A Japanese participant is defined as having both parents and 4 Japanese grandparents as confirmed by the interview. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan. Participant...
AZD7053 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, and the available trial focuses on evaluating its safety, tolerability, and pharmacokinetics in Japanese healthy participants.
AZD7053 is being developed by AstraZeneca PLC, which is listed on the stock exchange under the ticker AZN.
AZD7053 is in Phase 1 clinical development. The single completed trial, NCT06093542, was a Phase 1 study. AZD7053 is investigational and has not been approved by regulatory authorities.
AZD7053 has one completed clinical trial, NCT06093542, titled "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants." This Phase 1 study enrolled 12 healthy participants in Japan.
AZD7053 is the drug name, but the clinical trial NCT06093542 refers to it as AZD7503. This suggests that AZD7053 and AZD7503 may be alternative names for the same investigational drug, though the relationship is not explicitly confirmed.